Novel selective strategies targeting the BCL-2 family to enhance clinical efficacy in ALK-rearranged non-small cell lung cancer.

Cell Death Dis · 2025 · PMC11926089 · PMID 40113795

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

All four patient-derived cell lines (CUTO8, CUTO9, CUTO29, and YU1077) exhibited a clear trend in the increase of BCL2L11 mRNA after 24 h of treatment with alectinib, brigatinib, and lorlatinib (Fig. 2C ), correlating with the H3122 and H2228 cell lines data.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.